Results 21 to 30 of about 1,429,326 (362)

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials

Journal of Xenobiotics, 2023
Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali, Muhammad Yasir Anwar, Wajeeha Aiman, Gurneel Dhanesar, Zainab Omar, Mohammad Hamza, Maha Zafar, Harish Kumar Rengarajan, Michael Maroules   +8 more
doaj   +1 more source

Tyrosine kinases in rheumatoid arthritis [PDF]

Journal of Inflammation, 2011
Rheumatoid arthritis (RA) is an inflammatory, polyarticular joint disease. A number of cellular responses are involved in the pathogenesis of rheumatoid arthritis, including activation of inflammatory cells and cytokine expression. The cellular responses involved in each of these processes depends on the specific signaling pathways that are activated ...
Hiroshi Okamoto, Akiko Kobayashi
openaire   +4 more sources

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Nanomedicine of tyrosine kinase inhibitors

Theranostics, 2021
Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials.
Zita Goliasova, Petr Michalek, Petr Michalek, Veronika Smidova, Zbynek Heger, Zbynek Heger, Vojtech Adam, Vojtech Adam, Petr Hodek, Tomas Eckschlager   +9 more
openaire   +4 more sources

PTK2 and PTPN11 expression in myelodysplastic syndromes

Clinics, 2013
OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein ...
Mariana Lazarini, Joao Agostinho Machado-Neto, Leticia Frohlich Archangelo, Bruna Fernandes Mendes-Silva, Carolina Louzao Bigarella, Fabiola Traina, Sara Teresinha Olalla Saad   +6 more
doaj   +1 more source

QTC Changes Associated with Tyrosine Kinase Inhibitors in Cancer Patients

Pakistan Armed Forces Medical Journal, 2022
Objective: To look for QTc changes associated with Tyrosine Kinase inhibitors and factors related to these changes among patients suffering from cancer. Study Design: Comparative cross-sectional study.
Rahimullah Khattak, Riaz Ahmad, Muhammad Nadeem, Huma Amjad, Amjad Khan, Ibtisam .   +5 more
doaj   +1 more source

Tyrosine Kinase Inhibitors for the Elderly [PDF]

Journal of Cancer, 2016
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient.
Hohenforst-Schmidt, Wolfgang, Zarogoulidis, Paul, Steinheimer, Michael, Benhassen, Naim, Tsiouda, Theodora, Baka, Sofia, Yarmus, Lonny, Stratakos, Grigoris, Organtzis, John, Pataka, Athanasia, Tsakiridis, Kosmas, Karapantzos, Ilias, Karapantzou, Chrysanthi, Darwiche, Kaid, Zissimopoulos, Athanasios, Pitsiou, Georgia, Zarogoulidis, Konstantinos, Man, Yan-Gao, Rittger, Harald   +18 more
openaire   +4 more sources

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment? [PDF]

Reviews in Clinical Medicine, 2015
Chronic myelogenous leukemia is a myeloproliferative disorder presenting with anemia, elevated blood granulocytosis and the presence of immature granulocytes, basophilia, frequently thrombocytosis and spleen enlargement.
Hossein Rahimi, Zahra Mazloum Khorasani, Saeedeh Shariati   +2 more
doaj   +3 more sources

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Journal of Hematology & Oncology, 2018
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Guoshuang Shen, F. Zheng, Dengfeng Ren, F. Du, Qiuxia Dong, Ziyi Wang, Fuxing Zhao, Raees Ahmad, Jiuda Zhao   +8 more
semanticscholar   +1 more source